CLL-1 CAR-T

CLL-1 CAR-T is an investigational autologous chimeric antigen receptor (CAR) T-cell therapy developed by the Shenzhen Geno-Immune Medical Institute for the treatment of relapsed or refractory acute myeloid leukemia (AML). The therapy consists of T cells genetically modified via lentiviral vectors to express a CAR targeting C-type lectin-like molecule-1 (CLL-1, also known as CLEC12A), an antigen highly expressed on AML blasts and leukemic stem cells but absent on normal hematopoietic stem cells. The CAR construct utilizes a "4SCAR" design, which incorporates CD28, CD27, and CD3ζ costimulatory and activation domains to improve T-cell expansion and persistence. In clinical settings, it is often evaluated as part of a multi-target strategy (e.g., alongside CD33 or CD123 CAR-T cells) following lymphodepleting chemotherapy to maximize therapeutic efficacy against the heterogeneous cell populations in AML.

Other names

anti-CLL1 CAR-Tanti-CLL-1 CAR-Tanti-CLL 1 CAR-TCLL-1-specific CAR gene-engineered T cellsCLL1-specific CAR gene-engineered T cellsCLL 1-specific CAR gene-engineered T cellsCLL-1-specific CAR-T cellsCLL1-specific CAR-T cellsCLL 1-specific CAR-T cells